MedPath

Erdafitinib

Generic Name
Erdafitinib
Brand Names
Balversa
Drug Type
Small Molecule
Chemical Formula
C25H30N6O2
CAS Number
1346242-81-6
Unique Ingredient Identifier
890E37NHMV

Overview

In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy . Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.

Background

In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy . Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.

Indication

Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. The selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible FGFR genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic like the FDA-approved therascreen FGFR RGQ RT-PCR Kit as developed by QIAGEN. This above indication is approved under accelerated approval by the FDA based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Associated Conditions

  • Locally Advanced or Metastatic Urothelial Carcinoma (UC)

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/04/09
Phase 3
Not yet recruiting
2024/07/22
Phase 2
Recruiting
Spanish Oncology Genito-Urinary Group
2024/04/08
Phase 2
Active, not recruiting
2024/03/25
Not Applicable
Completed
2024/03/13
Phase 2
Active, not recruiting
2024/01/12
Early Phase 1
Not yet recruiting
2023/05/16
Phase 2
Recruiting
2022/10/05
Phase 1
Active, not recruiting
2022/10/03
Phase 2
Withdrawn
2022/04/07
Phase 1
Recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Janssen Products LP
59676-050
ORAL
5 mg in 1 1
2/1/2024
Janssen Products LP
59676-040
ORAL
4 mg in 1 1
2/1/2024
Janssen Products LP
59676-030
ORAL
3 mg in 1 1
2/1/2024

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
BALVERSA FILM-COATED TABLETS 4MG
SIN15987P
TABLET, FILM COATED
4.00 mg
8/7/2020
BALVERSA FILM-COATED TABLETS 3MG
SIN15986P
TABLET, FILM COATED
3.00 mg
8/7/2020
BALVERSA FILM-COATED TABLETS 5MG
SIN15988P
TABLET, FILM COATED
5.00 mg
8/7/2020

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Erdafitinib Tablets
国药准字HJ20250007
化学药品
片剂
1/8/2025
Erdafitinib Tablets
国药准字HJ20250008
化学药品
片剂
1/8/2025
Erdafitinib Tablets
国药准字HJ20250009
化学药品
片剂
1/8/2025

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath